Researchers from the Walter and Eliza Hall Institute have identified how pregnancy hormones send signals to critical molecules on the DNA to make changes in the epigenome. The epigenome is a series of chemical tags that modify DNA, controlling which genes are switched on and off.
Professor Visvader said the researchers had created a roadmap of the epigenomes of different breast cell types. In collaboration with Professor Gordon Smyth and colleagues from the institute’s Bioinformatics division they determined how the epigenomes changed in response to ovarian hormones such as progesterone.
“We found the epigenome was very sensitive to hormonal regulation,” Professor Visvader said. “This reveals another way in which female hormones can influence breast cancer risk – by altering the epigenome through modifications on the DNA.”
The epigenome is where the DNA and the environment intersect, communicating signals from the outside world to the DNA. The epigenome doesn’t alter the genetic code, but is a layer of proteins or tags that decorates the DNA and provides instructions on whether DNA should be read and ‘switched on’ to produce proteins.
The research team found that pregnancy hormones activate a molecule called EZH2, which is an important modifier of the epigenome. “We found that hormones including progesterone activate EZH2 to modify the epigenome, leading to global changes in the expression of a huge number of genes,” Professor Visvader said.
“In normal tissue, EZH2 is essential for the development of breast tissue including ducts and milk-producing cells, and for maintaining the activity of breast stem cells and their daughter progenitor cells. However, life-long exposure to hormones could lead to breast tumour initiation through increased levels of EZH2 and the changes that it orchestrates in the epigenome.”
Breast cancer is the most common cause of cancer in women, accounting for almost 30 per cent of all cancers affecting women. One in nine women in Australia will develop breast cancer by the age of 85.
High levels of EZH2 are a marker of poor prognosis in breast cancer and have been frequently observed in basal-like breast cancers, the most aggressive types of breast cancer. “The link between progesterone, EZH2 and the epigenome, could be crucially important in the very early stages of breast cancer development,” Professor Visvader said.
Professor Lindeman said there were decades of evidence linking hormone exposure with breast cancer, but the hormones’ influence on the epigenome was not known. “Our discovery points to a role for hormone-induced changes in the epigenome in the early stages of breast cancer initiation, and could lead to new therapeutics for treating breast cancer,” Professor Lindeman said. “Inhibitors against EZH2 are being developed by others, but it will be several years before we know the outcome of these on cancer.”
This project was supported by the National Health and Medical Research Council of Australia, the Victorian Government through funding of the Victorian Breast Cancer Research Consortium, the National Breast Cancer Foundation, and the Australian Cancer Research Foundation.
Media and Publications Manager
P: +61 3 9345 2928
M: +61 405 279 095